Posts Tagged ‘ADA2023’

“We may be on the cusp of an era of astonishing innovation – the limits of which aren’t even clear yet,” writes David Wallace-Wells in the New York Times. Among other breakthroughs, he cites the transformation in care that semaglutide and tirzepatide are bringing for the most prevalent chronic disease in the world – obesity. […]

We take it as a given – we want to eat healthy. Since 2016, FDA has been working on developing an updated definition for the meaning of “healthy” if a food seller wants to say that about one of its products. The agency is still struggling with this question today. So we were glad to […]

Suddenly at the ADA2023 meeting in San Diego, it seems the tides are rolling in to promise more options than ever before for treating obesity. By tides we mean all those drugs targeting the GLP-1 receptors. GLP-1 is shorthand for glucagon-like peptide 1. Most, but not all of these drugs making a splash in San […]

We’re packing our bag for San Diego and the 83rd Scientific Sessions of the American Diabetes Association, which starts on Friday. This is not a meeting that has been a regular habit for ConscienHealth. But this year it seems ADA2023 will be another milestone in the ongoing diabesity merger. That almost too clever term first […]